Matrix-Bio's goal is to be a leading provider of metabolomics-based testing in the fast-growing molecular diagnostic testing market. The company's first product, VeraMarker™ BCR, a blood test for detecting breast cancer and cancer recurrence monitoring, is being commercialized as the first metabolite-based test in the world. Matrix-Bio is currently exploring the commercial feasibility of additional diagnostics tests using its VeraMarker technology platform, including colon, esophageal, liver and pancreatic cancer; for identifying liver cancer in patients with hepatitis C; and for predicting preoperative chemotherapy effectiveness for breast cancer treatment.